オプションチェーンは、Predictive Oncologyの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Predictive Oncologyの市場センチメントを評価します。.

Predictive Oncology (NASDAQ:POAI) 株価情報, オプションチェーン

Predictive Oncology

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.

Predictive Oncology Inc

Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships.

Biotech

News

Legal

General

Korean Intellectual Property Office Granted Conduit Pharmaceuticals  Composition Of Matter Patent For AZD1656

Stephens &amp; Co. analyst Jim Salera reiterates Papa John's International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PZZA#NASDAQ">PZZA</a>) with a Overweight and maintains $50 price target.

Price Target

Reiteration

Analyst Ratings

PZZA

Stephens & Co. Reiterates Overweight on Papa John's International, Maintains $50 Price Target

Microchip Technology Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) shares are trading higher premarket on Friday after the company reported fourth-quarter&nbsp;results <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45300085/microchip-technology-announces-financial-results-for-fourth-quarter-and-fiscal-year-2025" rel="noreferrer noopener">after Thursday&#8217;s closing bell</a>.
Revenue fell 26.8% year over year (Y/Y)&nbsp;to $970.5 million, beating the analyst consensus estimate of&nbsp;$962.8 million.
In the quarter, the company achieved a book-to-bill ratio greater than one for the first time in almost three years.
Furthermore, the company stated that bookings in April surpassed the levels of any single month within that March quarter.
Adjusted EPS of&nbsp;11 cents was in line with the <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">analyst consensus estimate</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/45235394" rel="noreferrer noopener">Nvidia, Broadcom Lead Fund Manager Buys Even As Semiconductor Sector Cools: Analysts</a>
Dividend: The company declared a quarterly cash dividend of 45.5 cents per share, payable on June&nbsp;5, 2025, to stockholders <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45300086/microchip-technology-announces-quarterly-cash-dividend-on-common-stock-of-45-5-cents-per-share" rel="noreferrer noopener">of record as of May&nbsp;22, 2025</a>.&nbsp;
The company returned $1.066 billion to shareholders in the year through dividends and share repurchases.
Steve Sanghi, Microchip&#8217;s CEO and president said, &#8220;The decisive actions we have taken under our nine-point-plan are enhancing our operational capabilities through more efficient manufacturing, improving inventory management, and a renewed strategic focus.&#8221;
&#8220;A key highlight this quarter has been our inventory reduction strategy, with overall inventory dollars down $62.8 million, distribution inventory days reduced by 4 days to 33 days, and inventory days on our balance sheet decreased by 15 days from levels at December 31, 2024. We expect even more substantial inventory reduction in the June quarter as our manufacturing optimization actions are near completion.&#8221;
Eric Bjornholt, Microchip&#8217;s Chief Financial Officer, added, &#8220;During the quarter, we executed multiple financial actions that strengthened our balance sheet. These included reducing our total net debt by roughly $1.30 billion with a mandatory convertible preferred offering. We also amended and extended our revolving line of credit with more favorable terms and financial flexibility.&#8221;
Outlook:&nbsp;Microchip sees&nbsp;first-quarter adjusted EPS of&nbsp;18 to 26&nbsp;cents vs.&nbsp;consensus of 16&nbsp;cents and sales of&nbsp;$1.020 billion to $1.070 billion&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">vs.&nbsp;street view of $987.62 million</a>.
Investors can gain exposure to the stock via Tidal Trust II YieldMax Semiconductor Portfolio Option Income ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPY#NYSE">CHPY</a>) and First Trust S&amp;P 500 Diversified Dividend Aristocrats ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNGZ#NASDAQ">KNGZ</a>).
Price Action: MCHP shares are up 8.00% to $53.07 premarket at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45294428/wall-street-rallies-after-us-seals-first-trade-deal-you-better-go-out-and-buy-stock-trump-says" target="_blank" rel="noreferrer noopener">Wall Street Rallies After US Seals First Trade Deal: &#8216;You Better Go Out And Buy Stock,&#8217; Trump Says</a></li>
</ul>
Image via Shutterstock

Earnings

Equities

Large Cap

Guidance

Dividends

Movers

CHPY

KNGZ

MCHP

Microchip Technology Stock Gains On Uplifting Forecast

Barclays analyst Benjamin Budish maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Overweight and raises the price target from $13 to $14.

Barclays Maintains Overweight on P10, Raises Price Target to $14

TASK

Trading Halt: Halted at 8:29:01 a.m. ET - Trading Halt: Halt News Pending

Believes the Board Should Immediately Resume and Accelerate Buybacks
Asserts Board Should Remove Moshe&nbsp;Mizrahy as CEO of the Company
MIAMI, May 9, 2025 /PRNewswire/ --&nbsp;DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to continue its stock repurchase program and to replace its CEO.&nbsp;
The full text of the letter follows:
May 9th, 2025
To the Board Members of&nbsp;InMode:
For over a year, we have communicated publicly and privately with the Board of Directors of InMode (the "Board") about our concerns regarding the Company's capital allocation strategy and depressed valuation, with particular attention to the negative public statements and actions of CEO Moshe Mizrahy. During this period, InMode's stock price has continued to decline and Mr. Mizrahy's underperformance is clearly reflected in the Company's financials. Furthermore, we believe his reckless and antagonistic management style as CEO has gone unchecked.
Following Mr.&nbsp;Mizrahy's most recent comments, we are compelled to underscore the danger of allowing him to make financially uninformed public statements regarding capital allocation. In discussing recent buybacks, he said: "Now, actually from an investment point of view of the company, we actually invested $500 million, but it did not help the stock price. The stock price is around $15 today. So basically, it was not the best -- the best investment from the corporation point of view, and I'm sure it was not the best investment from the shareholders' point of view."i&nbsp;
These remarks are both incorrect and damaging. The purpose and value of these&nbsp;buybacks is not in moving the short-term stock price, it is in creating long-term value for shareholders. We believe InMode's depressed stock price is a direct result of Mr. Mizrahy's dismal leadership and poor performance as CEO, which is further reflected in the financials of the Company.ii
Mr.&nbsp;Mizrahy's incorrect and misleading public commentary on how buybacks are meant to work, alongside his continued lack of financial results, are driving down the price of the Company's stock.iii We will not speculate on Mr. Mizrahy motivations, but InMode's shareholders are suffering because of his words and actions as CEO. The Board, in its legal and fiduciary duty to represent all investors, must take action on their behalf.
In our view, the Board should immediately resume the Share Repurchase Program and "substantial additional capital return" announced in Februaryiv, and the Board should remove Moshe Mizrahy from his position as the CEO of the Company.
Whether or not Mr.&nbsp;Mizrahy understands how buybacks are meant to work, we expect the members of this Board to possess the financial literacy to know the value they can add to shareholders. The Board must work to immediately remedy the situation, restating the Company's commitment to returning the cash on the balance sheet to its owners: the shareholders.
InMode's buybacks should be resumed immediately; the Company's stock price remains a bargain due to continued mismanagement and Mr. Mizrahy's harmful public remarks. Cash sitting on the balance sheet produces no earnings and no shareholder return. Management's prior attempts at M&amp;A have all failed. The value that is created from executing buybacks now will come to fruition when a new CEO steps in to manage the business and earnings acceleration resumes. The lower the Company's stock price and valuation, the more aggressive the Board should be returning the cash to shareholders in the form of buybacks. As the Company buys back its own stock, it is impossible to pick the bottom – what matters is to continue the buybacks as long as the price remains attractive. The Company currently holds approximately 60% of its market cap in cash, maintains no debt and has plenty of free cash flow.v The money sitting on the balance sheet belongs to your shareholders and the most accretive way to return that money, until the valuation improves considerably, is through continued buybacks.
Mr.&nbsp;Mizrahy has lowered guidance almost every quarter since Q3 2023vi. He chose to fire the US Head of Sales –InMode's largest market – right before the Company's most important quarter.vii&nbsp;It should be no surprise that the US business is underperforming. In a recent letter to DOMA, Mr. Mizrahy refused to consider moving a portion of production outside of Israel, a move that would decrease potential risks as well as help to trim costs and grow margins, and claimed that he doubted the facilities in the Dominican Republic or Costa Rica are FDA-approved.viii A simple online search would have clarified the sizable number of medical tech companies, many of which are significantly larger than InMode, with production facilities in these countries.ix Shareholders deserve better than Mr. Mizrahy's antagonistic and uniformed approach to management. We maintain that the Board should remove Mr. Mizrahy from his position and replace him with someone better equipped to lead InMode.&nbsp;
In our opinion, the Company must take action to protect the brand, including Morpheus8. It is a mistake to not increase prices, which the market should bear. Lowering margins hurts shareholders.
As of May 7th,&nbsp;InMode's market capitalization – discounting the approximately $500 million dollars in cash – is barely $375 million.x This confers a value of only $375 million for&nbsp;InMode's inventory, worldwide distribution, global installed base in the tens of thousands, unique IP, unparalleled research team, brands like Morpheus8, its recurring disposable business and extended guarantee business, plus more than $100 million of free cash flow.xi It is our conviction that InMode's current valuation is divorced from the reality of its excellent business, which maintains gross margins of nearly 80% even under this underperforming CEO.
The Board's legal and fiduciary duties to its shareholders require it to act in the face of a depressed valuation and persistent underperformance. We believe the business and its shareholders will be best served by removing Mr. Mizrahy from his position and reinstating and accelerating the share buyback program.
Sincerely,
Pedro&nbsp;Escudero CEO &amp; CIO DOMA Perpetual Capital Management LLC

INMD

DOMA Perpetual Capital Management Urges InMode Board to Resume Stock Buyback, Replace CEO

Seaport Global analyst Jay Goldberg initiates coverage on Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) with a Neutral rating.

Initiation

QCOM

Seaport Global Initiates Coverage On Qualcomm with Neutral Rating

Barclays analyst Eddie Kim maintains Innovex International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVX#NYSE">INVX</a>) with a Underweight and lowers the price target from $16 to $13.

INVX

Barclays Maintains Underweight on Innovex International, Lowers Price Target to $13

Barclays analyst Raimo Lenschow maintains Appian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPN#NASDAQ">APPN</a>) with a Underweight and raises the price target from $28 to $33.

APPN

Barclays Maintains Underweight on Appian, Raises Price Target to $33

Barclays analyst Kannan Venkateshwar maintains Altice USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATUS#NYSE">ATUS</a>) with a Equal-Weight and raises the price target from $2 to $3.

ATUS

Barclays Maintains Equal-Weight on Altice USA, Raises Price Target to $3

Benchmark analyst David Williams reiterates MACOM Technology Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>) with a Buy and maintains $160 price target.

MTSI

Benchmark Reiterates Buy on MACOM Technology Solns, Maintains $160 Price Target

Spectral Medical (TSX:<a class="ticker" href="https://www.benzinga.com/stock/EDT#TSX">EDT</a>) reported quarterly losses of $(0.04) per share. This is a 300 percent decrease over losses of $(0.01) per share from the same period last year. The company reported $572.00 thousand in sales this quarter. This is a 14.37 percent decrease over sales of $668.00 thousand the same period last year.

TSX:EDT

Spectral Medical Q1 EPS $(0.04) Down From $(0.01) YoY, Sales $572.00K Down From $668.00K YoY

As of May 9, 2025, three stocks in the industrials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">LYFT Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>)</h3>
<ul class="wp-block-list">
<li>On May 8, Lyft reported better-than-expected first-quarter EPS results. Also, the company announced a $750 million share buyback plan. &#8220;Q1 marked Lyft&#8217;s 16th consecutive quarter of double-digit year on year Gross Bookings growth demonstrating the resilience and momentum of our customer-obsessed strategy,&#8221; said Lyft CEO David Risher. The company's stock jumped around 15% over the past month and has a 52-week high of $19.06.</li>
<li>RSI Value: 70.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>LYFT Price Action: Shares of Lyft gained 3.3% to close at $13.00 on Thursday.</li>
<li>Edge Stock Ratings: 21.41 Momentum score with Value at 13.13. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/lyft"><img loading="lazy" decoding="async" width="478" height="182" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09044835/image-99.png" alt="" class="wp-image-909747" style="width:297px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09044835/image-99.png 478w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09044835/image-99-300x114.png 300w" sizes="(max-width: 478px) 100vw, 478px" /></a></figure>
<h3 class="wp-block-heading">Matrix Service Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTRX#NASDAQ">MTRX</a>)</h3>
<ul class="wp-block-list">
<li>On May 7, Matrix Service posted downbeat quarterly results. &#8220;Our third quarter results reflect accelerating revenue, supported by backlog growth which advances our return to profitability and enhances our visibility into future earnings,&#8221; said John Hewitt, President and Chief Executive Officer of Matrix Service Company. The company's stock gained around 25% over the past month and <a href="https://www.benzinga.com/quote/MTRX">has a 52-week high</a> of $15.75.</li>
<li>RSI Value: 74.6</li>
<li>MTRX Price Action: Shares of Matrix Service gained 11.3% to close at $13.65 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Manitowoc Company Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTW#NYSE">MTW</a>)</h3>
<ul class="wp-block-list">
<li>On May 6, Manitowoc posted weaker-than-expected quarterly results. &#8220;First-quarter results exceeded our expectations. We began to see signs of a turnaround in our Europe tower crane business with machine orders up 68% year-over-year, marking the third consecutive quarter of year-over-year growth,&#8221; said Aaron Ravenscroft, President and Chief Executive Officer of The Manitowoc Company, Inc. The company's stock gained around 22% over the past month and has a <a href="https://www.benzinga.com/quote/MTW">52-week high</a> of $13.46.</li>
<li>RSI Value: 78.3</li>
<li>MTW Price Action: Shares of Manitowoc gained 14.7% to close at $9.82 on Thursday.</li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>. 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45285413/top-3-financial-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Financial Stocks Which Could Rescue Your Portfolio This Month</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

LYFT

MTRX

Top 3 Industrials Stocks That May Collapse In May

Small Cap Consumer Research analyst Eric Beder reiterates Betterware de Mexico SAPI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>) with a Buy and maintains $22.5 price target.

BWMX

Small Cap Consumer Research Reiterates Buy on Betterware de Mexico SAPI, Maintains $22.5 Price Target

Americas Gold And Silver (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/USAS#AMEX">USAS</a>) reported quarterly losses of $(0.03) per share. This is a 57.14 percent increase over losses of $(0.07) per share from the same period last year. The company reported $23.55 million in sales this quarter. This is a 20.82 percent increase over sales of $19.49 million the same period last year.

TSX:USA

USAS

Americas Gold And Silver Q1 EPS $(0.03) Up From $(0.07) YoY, Sales $23.55M Up From $19.49M YoY

PMV Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMVP#NASDAQ">PMVP</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.37) by 8.11 percent. This is a 13.33 percent decrease over losses of $(0.30) per share from the same period last year.

Earnings Beats

PMVP

PMV Pharma Q1 EPS $(0.34) Beats $(0.37) Estimate

Needham analyst Bernie McTernan reiterates Peloton Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) from Hold to Hold.

PTON

Needham Reiterates Hold on Peloton Interactiveto Hold

WIIM

PAR stock has given up its prior gain. PAR Technology shares were trading higher after the company reported better-than-expected Q1 adjusted EPS results.

Barclays analyst Gena Wang maintains 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) with a Overweight and lowers the price target from $45 to $38.

FDMT

Barclays Maintains Overweight on 4D Molecular Therapeutics, Lowers Price Target to $38

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.5% on Friday.
Shares of Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) fell sharply in today's pre-market trading after the company reported <a href="https://in.benzinga.com/general/travel/25/05/45303916/expedia-stock-trades-down-on-q1-revenue-miss-weaker-than-expected-demand-in-the-us">worse-than-expected Q1 sales results.</a>
Expedia reported first-quarter revenue of $2.99 billion, up 3% year-over-year. The revenue total missed a Street consensus estimate of $3.01 billion according to data from Benzinga Pro.
Expedia Group shares dipped 9.8% to $152.40 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Jade Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBIO#NASDAQ">JBIO</a>) shares tumbled 44.4% to $5.00 in pre-market trading.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) shares dipped 35.6% to $2.04 in pre-market trading after the company reported worse-than-expected first-quarter financial results.</li>
<li>Profound Medical Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROF#NASDAQ">PROF</a>) fell 34.7% to $3.25 in pre-market trading after posting downbeat quarterly earnings.</li>
<li>Globus Medical, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) tumbled 17.2% to $60.00 in pre-market trading after the company reported worse-than-expected first-quarter financial results and cut its FY25 adjusted EPS guidance below estimates.</li>
<li>FIGS, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>) fell 16.2% to $4.22 in pre-market trading after reporting first-quarter results.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) declined 13.2% to $3.84 in pre-market trading after reporting mixed quarterly results.</li>
<li>Onto Innovation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) dipped 11.6% to $112.00 in pre-market trading after the company issued weak forecast for the second quarter.</li>
<li>OUTFRONT Media Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUT#NYSE">OUT</a>) declined 7% to $14.31 in pre-market trading following downbeat quarterly results.</li>
<li>Grindr Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) dipped 6.7% to $22.80 in pre-market trading after the company reported worse-than-expected quarterly sales results.</li>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) dipped 6.3% to $50.82 in pre-market trading following third-quarter results.</li>
<li>HubSpot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) fell 4.7% to $629.00 in pre-market trading after the company reported first0quarter financial results. The company issued second-quarter adjusted EPS guidance below estimates.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45285413/top-3-financial-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Financial Stocks Which Could Rescue Your Portfolio This Month</a> </li>
</ul>
Photo via Shutterstock

AFRM

EXPE

FIGS

GMED

GRND

HUBS

IOVA

JBIO

ONTO

PROF

WOLF

Expedia, Wolfspeed, HubSpot And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Press Releases

Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences

Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology

Milestone Merger Payment made with Predictive Oncology to Advance AI-Driven Biomarker Discovery and Precision Medicine in Cancer and Beyond: Renovaro, Inc. (NASDAQ: RENB)

Health Care

Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries

Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary

Breakthroughs and Discoveries: TNON, PNPN.V, POAI, DYAI, PRSO, Drive Innovation Across Sectors

Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update

Renovaro Provides Update to Definitive Agreement with Predictive Oncology

Predictive Oncology Develops Novel Approach to Identifying Clinically Viable Abandoned Drugs

Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth

Comments

Predictive Oncology

Predictive Oncology (POAI) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル